×

Intellectual Property Patents

  • Feb 21- The U.S. Supreme Court on Tuesday turned away an appeal by Boston Scientific Corp of a Maryland state court jury verdict ordering the medical device company to pay $308 million to a patent licensor for breach of contract concerning implantable cardiac devices. Boston Scientific had asked the justices to hear its appeal in the dispute over its licenses...

  • In a statement, Berkeley said it respects the ruling, but that it will "carefully consider all options for possible next steps in this legal process, including the possibility of an appeal." The patent dispute involved work led by Feng Zhang of the Broad Institute and Jennifer Doudna and Emmanuelle Charpentier at Berkeley. Lawyers for Berkeley maintained that...

  • Feb 15- The Broad Institute, a biological and genomic research center affiliated with MIT and Harvard, will keep valuable patents on a revolutionary gene-editing technology known as CRISPR, a U.S. patent agency ruled on Wednesday. Patent and Trademark Office's Patent Trial and Appeal Board in Alexandria, Virginia, rejected a claim by a rival team, associated...

  • Feb 15- The Broad Institute, a biological and genomic research center affiliated with MIT and Harvard, will keep valuable patents on a revolutionary gene-editing technology known as CRISPR, a U.S. patent agency ruled on Wednesday. Patent and Trademark Office's Patent Trial and Appeal Board in Alexandria, Virginia, rejected a claim by a rival team, associated...

  • Feb 15- The Broad Institute, a biological and genomic research center affiliated with MIT and Harvard, will keep valuable patents on a revolutionary gene-editing technology known as CRISPR, a U.S. patent agency ruled on Wednesday. Patent and Trademark Office's Patent Trial and Appeal Board in Alexandria, Virginia, rejected a claim by a rival team, associated...

  • Patent and Trademark Office's Patent Trial and Appeal Board in Alexandria, Virginia on Wednesday dismissed a claim by a rival team, associated with the University of California at Berkeley and the University of Vienna in Austria, to have invented the technology first.

  • Feb 8- A U.S. appeals court on Wednesday has stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, later this month while they appeal. A federal judge had earlier blocked sales of the drug after rival Amgen Inc won a trial in which it accused them of infringing its patents.

  • Jan 31- A bitter defeat in a U.S. patents case sent shares in Teva Pharmaceutical Industries plummeting on Tuesday, the latest in a series of setbacks that has investors calling for major changes at the world's largest generic drugmaker. A U.S. District Court on Monday rejected four out of five of Israel- based Teva's claims of patent infringement on its...

  • Jan 30- Teva Pharmaceutical Industries Ltd said on Monday a U.S. court rejected four of the Israel- based drugmaker's claims of patent infringement on its top-selling multiple sclerosis treatment. The rejection comes four months after U.S. patent officials invalidated three patents on its drug Copaxone, in response to challenges by pharmaceutical company...

  • Ed Lee: Apple's jumping on the wave against Qualcomm

    Discussing Apple's lawsuit against Qualcomm over several issues like fees and patents with Ed Lee, Recode managing editor.

  • People walk past Qualcomm's stand during the Mobile World Congress in Barcelona, Spain February 24, 2016.

    Instinent says Qualcomm needs approval for its NXP Semiconductors merger from U.S., China, Japan, South Korea, Taiwan and the EU.

  • Merck will make an initial payment of $625 million to Bristol and Japan's Ono. Bristol and Ono, which co-developed the first PD-1 antibody called Opdivo, filed the suit against Merck in September 2014, alleging that its sale of Keytruda, also a PD-1 antibody, infringed their patents in markets including the United States, parts of Europe, Australia and Japan.

  • WASHINGTON, Jan 18- The U.S. International Trade Commission said on Wednesday it had launched on investigation into whether Fujifilm Holdings Corp was violating patents which Sony Corp holds for certain magnetic tape cartridges.

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of using "anticompetitive" tactics to maintain its monopoly on a key semiconductor used in mobile phones. The FTC, which works with the Justice Department to enforce antitrust law, said that San Diego- based Qualcomm used its dominant...

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of using "anticompetitive" tactics to maintain its monopoly on a key semiconductor used in mobile phones. The FTC, which works with the Justice Department to enforce antitrust law, said that San Diego- based Qualcomm used its dominant...

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of antitrust violations in its patent licensing business. The FTC asked the U.S. District Court for the Northern District of California in San Jose to order Qualcomm to cease this and related practices. In February 2015, Qualcomm paid a $975...

  • Jan 17- Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to license the Danish company's patents covering multiple sclerosis drugs including Biogen's flagship drug, Tecfidera. "We believe this agreement will clarify and strengthen our intellectual property for Tecfidera," said Biogen Chief Executive Michel Vounatsos said in a...

  • Jan 9- Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schleifer said Amgen had refused a request to...

  • Jan 9- Regeneron Pharmaceuticals Chief Executive Len Schliefer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schliefer said Amgen had refused a request to...

  • Jan 5- Regeneron Pharmaceuticals Inc and Sanofi SA said on Thursday they would appeal the U.S. District Court ruling which banned the two companies from selling their cholesterol drug, Praluent, on grounds of patent infringement. District Judge Sue Robinson in Delaware had ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to...